MX2022016589A - O-antigeno de klebsiella pneumoniae. - Google Patents

O-antigeno de klebsiella pneumoniae.

Info

Publication number
MX2022016589A
MX2022016589A MX2022016589A MX2022016589A MX2022016589A MX 2022016589 A MX2022016589 A MX 2022016589A MX 2022016589 A MX2022016589 A MX 2022016589A MX 2022016589 A MX2022016589 A MX 2022016589A MX 2022016589 A MX2022016589 A MX 2022016589A
Authority
MX
Mexico
Prior art keywords
klebsiella pneumoniae
antigen vaccine
antigen
immunogenic compositions
vaccines
Prior art date
Application number
MX2022016589A
Other languages
English (en)
Inventor
Michael Thomas Kowarik
Stefan Jochen Kemmler
Sandmeier Maria Paula Carranza
Rainer Follador
Veronica Gambillara Fonck
Patricia Martin Killias
Gerd Martin Lipowsky
Gerald Johann Posch
Fabio Serventi
Dominique Nicolas Sirena
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2022016589A publication Critical patent/MX2022016589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99019—Undecaprenyl-diphosphooligosaccharide—protein glycotransferase (2.4.99.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se relaciona con el campo de las composiciones inmunogénicas y vacunas, su fabricación, las células huésped que pueden utilizarse en su fabricación y el uso de tales composiciones inmunogénicas y vacunas en la medicina. Más en particular, se relaciona con O-antígenos de Klebsiella pneumoniae, conjugados que comprenden un O-antígeno de K. pneumoniae, las células huésped adecuadas para su producción y composiciones inmunogénicas o vacunas que contienen al menos un O-antígeno de Klebsiella pneumoniae.
MX2022016589A 2020-06-25 2021-06-17 O-antigeno de klebsiella pneumoniae. MX2022016589A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063043883P 2020-06-25 2020-06-25
EP20182139 2020-06-25
EP20182138 2020-06-25
PCT/EP2021/066343 WO2021259743A2 (en) 2020-06-25 2021-06-17 Vaccine

Publications (1)

Publication Number Publication Date
MX2022016589A true MX2022016589A (es) 2023-02-01

Family

ID=76375084

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022016589A MX2022016589A (es) 2020-06-25 2021-06-17 O-antigeno de klebsiella pneumoniae.
MX2022015734A MX2022015734A (es) 2020-06-25 2021-06-17 Proteinas de exotoxina a modificadas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015734A MX2022015734A (es) 2020-06-25 2021-06-17 Proteinas de exotoxina a modificadas.

Country Status (8)

Country Link
US (2) US20230293657A1 (es)
EP (2) EP4171624A1 (es)
JP (2) JP2023531242A (es)
CN (2) CN116209753A (es)
BR (2) BR112022023234A2 (es)
CA (2) CA3185639A1 (es)
MX (2) MX2022016589A (es)
WO (2) WO2021259742A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4347625A1 (en) * 2021-05-26 2024-04-10 Pfizer Inc. Recombinant expression of klebsiella pneumoniae o-antigens in escherichia coli
WO2023118033A1 (en) * 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
WO2024089001A1 (en) * 2022-10-24 2024-05-02 Idorsia Pharmaceuticals Ltd Vaccine against klebsiella pneumoniae

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0911036A3 (en) 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
AU712981B2 (en) 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2311972B1 (en) 2005-05-11 2015-01-21 ETH Zurich Recombinant N-glycosylated proteins from procaryotic cells
HUE039413T2 (hu) 2008-02-20 2018-12-28 Glaxosmithkline Biologicals Sa Prokarióta sejtekbõl származó rekombináns N-glikozilált fehérjékbõl készített biokonjugátumok
JP2012533285A (ja) 2009-07-17 2012-12-27 オーシャン ハーベスト テクノロジー （カナダ） インコーポレイテッド 魚用飼料中の合成添加物を置換する、天然かつ持続可能な海藻配合物
DK2501406T3 (en) 2009-11-19 2018-02-26 Glaxosmithkline Biologicals Sa BIOSYNTHESE SYSTEM PRODUCING IMMUNOGENIC POLYSACCHARIDES IN PROCARYOTIC CELLS
DK2566507T3 (da) 2010-05-06 2018-01-29 Glaxosmithkline Biologicals Sa Biokonjugatvacciner med kapselformige grampositive bakterier
AU2013311534A1 (en) 2012-09-10 2015-03-12 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
EP2906681B1 (en) 2012-10-12 2019-01-09 GlaxoSmithKline Biologicals S.A. Methods of host cell modification
SG11201503308XA (en) 2012-11-07 2015-05-28 Glycovaxyn Ag PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION
WO2015052344A1 (en) 2013-10-11 2015-04-16 Glycovaxyn Ag Methods of host cell modification
AR100859A1 (es) 2014-02-24 2016-11-09 Glycovaxyn Ag Polisacáridos y sus usos
AR104469A1 (es) 2014-08-08 2017-07-26 Glycovaxyn Ag Células huésped modificadas para su uso en producción de bioconjugados
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
EP3492481A1 (en) * 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae

Also Published As

Publication number Publication date
EP4171624A1 (en) 2023-05-03
BR112022024267A2 (pt) 2023-01-17
WO2021259743A2 (en) 2021-12-30
CN116209753A (zh) 2023-06-02
MX2022015734A (es) 2023-01-18
WO2021259743A3 (en) 2022-04-21
US20230226175A1 (en) 2023-07-20
CA3185639A1 (en) 2021-12-30
CA3185642A1 (en) 2021-12-30
JP2023531059A (ja) 2023-07-20
EP4171625A2 (en) 2023-05-03
WO2021259742A1 (en) 2021-12-30
CN115996749A (zh) 2023-04-21
BR112022023234A2 (pt) 2023-01-03
US20230293657A1 (en) 2023-09-21
JP2023531242A (ja) 2023-07-21

Similar Documents

Publication Publication Date Title
MX2022016589A (es) O-antigeno de klebsiella pneumoniae.
CL2017003193A1 (es) Composiciones que comprenden cepas bacterianas
BR112012022676A2 (pt) composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit
CL2017003192A1 (es) Composiciones que comprenden cepas bacterianas
EA201691478A1 (ru) Новый полисахарид и его применения
CO6460761A2 (es) Vacuna viva modificada de mycoplasma bovis mejorada, métodos de producción de vacunas vivas de mycoplasma bovis, vacunas de combinación y métodos de tratamiento
BRPI0710918A2 (pt) Formulações as quais estabilizam conjugados de polissacarídeo-proteína,composições de peptidase c5a estreptocócica e composição de proteína 2086 de n. meningitidis,bem como formulações que inibem a agregragação induzida por silicone de um conjugado de polissacarídeo-proteína, a agregação induzida por silicone de uma composição de peptidade c5a estreptocócica e a agregação induzida por silicone de uma composição de proteína 2086 de n.meningitidi
EP3556353A3 (en) Lipid nanoparticle vaccine adjuvants and antigen delivery systems
BR112012022800A2 (pt) composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX2010003719A (es) Vacuna de mycoplasma bovis y metodos de uso de la misma.
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
GB201010758D0 (en) Bioactive glass composition
BR112015030229A8 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
AR118389A1 (es) Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
BR112015004463A2 (pt) dispositivo hiperbárico e processos para produzir vacinas inativadas e para redobrar/solubilizar proteínas recombinantes
CO2021001926A2 (es) Composiciones de escherichia coli y métodos de estas
GB2539148A (en) Vaccine compositions
BR112016025977A2 (pt) composições, métodos e utilizações para formulações de papilomavirus humano estábulo estável
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
MX2016013559A (es) Formulaciones de proteina estables que comprenden un exceso molar de sorbitol.
MX2018012270A (es) Novedosas formulaciones de vacuna neumococica.
AR093424A1 (es) Vacunas atenuadas de mannheimia haemolytica y metodos para su elaboracion y uso